ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,140Medicare Part D Prescriptions Filled, Including Refills

Rank: 110 out of 910

$576K Total Retail Price of All Prescriptions

Rank: 123 out of 910

825 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
6% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arizona
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 825 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

8% of this provider’s 825 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 9,584 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arizona
SIMVASTATIN 573 538 1 3
LEVOTHYROXINE SODIUM 489 467 2 1
LISINOPRIL 419 391 3 2
OMEPRAZOLE 391 380 4 5
FUROSEMIDE 297 288 5 9
HYDROCHLOROTHIAZIDE 236 214 6 12
WARFARIN SODIUM 226 226 7 11
METOPROLOL TARTRATE 216 213 8 7
METOPROLOL SUCCINATE 213 197 9 21
HYDROCODONE-ACETAMINOPHEN 197 180 S3 10 8
AMLODIPINE BESYLATE 182 176 11 4
ATENOLOL 179 176 12 10
ZOLPIDEM TARTRATE 173 163 13 17
CITALOPRAM HBR 144 133 14 19
TAMSULOSIN HCL 126 126 15 29
LOVASTATIN 125 116 16 20
METFORMIN HCL 121 120 17 6
CIPROFLOXACIN HCL 106 104 18 48
GABAPENTIN 104 96 19 13
TRAMADOL HCL 102 94 20 25
SERTRALINE HCL 101 98 21 24
TRIAMTERENE-HCTZ 101 91 21 39
POTASSIUM CHLORIDE 97 93 23 18
ATORVASTATIN CALCIUM 91 79 24 14
ALENDRONATE SODIUM 87 87 25 22
DIGOXIN 86 86 26 64
ALLOPURINOL 80 78 27 33
PANTOPRAZOLE SODIUM 80 70 27 27
AZITHROMYCIN 78 77 29 41
FLUTICASONE PROPIONATE 77 72 30 23
OXYCODONE-ACETAMINOPHEN 75 56 S2 31 31
HYDRALAZINE HCL 74 70 32 65
CLOPIDOGREL 71 63 33 35
PRAVASTATIN SODIUM 67 67 34 16
MELOXICAM 65 64 35 76
GLIPIZIDE ER 59 59 36 87
CELEBREX 58 58 37 85
FINASTERIDE 56 56 38 59
DOXAZOSIN MESYLATE 56 55 38 62
OXYBUTYNIN CHLORIDE ER 55 53 40 111
CRESTOR 54 53 41 26
CLONIDINE HCL 54 54 41 51
KLOR-CON 10 54 54 41 88
LOSARTAN POTASSIUM 54 52 41 15
GEMFIBROZIL 51 46 45 63
DIOVAN 51 51 45 34
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 24, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.